13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001346824
Total reported value
$11.5B
$11.5B
89 檔
28.2%
At the close of Q4 2024, Ra Capital Management, L.p. disclosed equity holdings valued at approximately $11.5B, spread across 89 reported holdings.
Ra Capital Management, L.p. executed strategic sector rebalancing during Q4 2024, establishing 17 new positions while fully exiting 9 holdings and trimming 16 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | Stock-Other | 18.53% | -24.92% | EXIT | |
| 2 | PCVX | Vaxcyte Inc | Stock-Other | 9.47% | -1.27% | — | |
| 3 | JANX | Janux Therapeutics Inc | Stock-Other | 7.39% | -0.16% | +13.09% | |
| 4 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.53% | +0.29% | — | |
| 5 | LEGN | Legend Biotech Corp-adr | Stock-Other | 3.25% | — | — | |
| 6 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 3.17% | -0.52% | — | |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.03% | -0.43% | +9.69% | |
| 8 | WVE | Wave Life Sciences Ltd. | Stock-Other | 3.00% | -0.71% | — | |
| 9 | ACLXGBX | Arcellx Inc | Stock-Other | 2.84% | — | +50.55% | |
| 10 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.44% | — | — | |
| 11 | SEPN | Septerna Inc | Stock-Other | 2.13% | +0.26% | — | |
| 12 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.00% | — | — | |
| 13 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.97% | -1.56% | +2.12% | |
| 14 | RXST | Rxsight Inc | Stock-Other | 1.71% | — | -4.44% | |
| 15 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.61% | +0.34% | — | |
| 16 | LENZ | Lenz Therapeutics Inc | Stock-Other | 1.61% | -0.20% | — | |
| 17 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.52% | -0.16% | — | |
| 18 | ETNBGBP | 89bio Inc | Stock-Other | 1.48% | — | — | |
| 19 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 1.47% | — | — | |
| 20 | GERN | Geron CORP | Stock-Other | 1.41% | -0.53% | -7.05% | |
| 21 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 1.32% | +0.84% | — | |
| 22 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.13% | — | — | |
| 23 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.09% | — | -64.73% | |
| 24 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.97% | — | -26.88% | |
| 25 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.95% | — | -20.00% | |
| 26 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.79% | -0.41% | — | |
| 27 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.78% | -1.28% | EXIT | |
| 28 | CLYM | Climb Bio Inc | Stock-Other | 0.75% | +0.46% | — | |
| 29 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.69% | — | -49.79% | |
| 30 | TRML | Tourmaline Bio Inc | Stock-Other | 0.69% | — | — | |
| 31 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.67% | +0.07% | — | |
| 32 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.64% | -0.49% | EXIT | |
| 33 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.63% | — | — | |
| 34 | GHRS | GH Research PLC | Stock-Other | 0.62% | +0.64% | — | |
| 35 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.61% | — | — | |
| 36 | VOR | Vor Biopharma Inc. | Stock-Other | 0.59% | — | +74.28% | |
| 37 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.55% | — | -20.00% | |
| 38 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.54% | -2.32% | EXIT | |
| 39 | PEPG | Pepgen Inc | Stock-Other | 0.54% | -0.07% | — | |
| 40 | EVH | Evolent Health Inc - A | Stock-Other | 0.54% | — | -57.99% | |
| 41 | KURA | Kura Oncology Inc | Stock-Other | 0.52% | — | — | |
| 42 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.46% | — | — | |
| 43 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.45% | -0.19% | — | |
| 44 | CMRXEUR | Chimerix Inc | Stock-Other | 0.41% | — | — | |
| 45 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.39% | — | +55.43% | |
| 46 | MBX | Mbx Biosciences Inc | Stock-Other | 0.37% | — | — | |
| 47 | NKTX | Nkarta Inc | Stock-Other | 0.36% | +0.03% | — | |
| 48 | ABOS | Acumen Pharmaceuticals Inc | Stock-Other | 0.34% | -0.03% | — | |
| 49 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.34% | +0.08% | -10.49% | |
| 50 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.33% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | JANX | Janux Therapeutics Inc | +2.6% | +13.09% | Add |
| 2 | SEPN | Septerna Inc | +2.1% | NEW | New buy |
| 3 | ASND | Ascendis Pharma A/S | +1.8% | +4.14% | Add |
| 4 | NAMS | NewAmsterdam Pharma Company N.V. | +1.5% | +9.69% | Add |
| 5 | XBI | Ss Spdr S&p Biotech ETF | +1.5% | NEW | New buy |
| 6 | WVE | Wave Life Sciences Ltd. | +1.3% | — | Unchanged |
| 7 | ACLXGBX | Arcellx Inc | +1.1% | +50.55% | Add |
| 8 | RYTM | Rhythm Pharmaceuticals Inc | +0.9% | — | Unchanged |
| 9 | TXG | 10x Genomics Inc-class A | +0.6% | NEW | New buy |
| 10 | KURA | Kura Oncology Inc | +0.5% | NEW | New buy |
| 11 | LENZ | Lenz Therapeutics Inc | +0.5% | — | Unchanged |
| 12 | ZLAB | Zai Lab Ltd-adr | +0.5% | NEW | New buy |
| 13 | EWTX | Edgewise Therapeutics Inc | +0.4% | — | Unchanged |
| 14 | VOR | Vor Biopharma Inc. | +0.4% | +74.28% | Add |
| 15 | NRIX | Nurix Therapeutics Inc | +0.3% | NEW | New buy |
| 16 | EYPT | Eyepoint Inc | +0.3% | NEW | New buy |
| 17 | CMRXEUR | Chimerix Inc | +0.3% | — | Unchanged |
| 18 | CDTX | Cidara Therapeutics Inc | +0.3% | +55.43% | Add |
| 19 | CBLL | Ceribell Inc | +0.3% | NEW | New buy |
| 20 | TVTX | Travere Therapeutics Inc | +0.3% | NEW | New buy |
| 21 | PRAX | Praxis Precision Medicines I | +0.3% | — | Unchanged |
| 22 | ETNBGBP | 89bio Inc | +0.3% | — | Unchanged |
| 23 | ALEC | Alector Inc | +0.2% | NEW | New buy |
| 24 | DRUG | Bright Minds Biosciences Inc | +0.2% | NEW | New buy |
| 25 | FULC | Fulcrum Therapeutics Inc | +0.2% | — | Unchanged |
| 26 | ELDN | Eledon Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 27 | TARA | Protara Therapeutic Inc | +0.2% | +78.95% | Add |
| 28 | ACRS | Aclaris Therapeutics Inc | +0.2% | NEW | New buy |
| 29 | MNPR | Monopar Therapeutics Inc | +0.2% | NEW | New buy |
| 30 | MLYS | Mineralys Therapeutics Inc | +0.1% | — | Unchanged |
| 31 | ✓ | +0.1% | — | Unchanged | |
| 32 | GHRS | GH Research PLC | +0.1% | — | Unchanged |
| 33 | AXSM | Axsome Therapeutics Inc | +0.1% | — | Unchanged |
| 34 | ENTA | Enanta Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 35 | SERA | Sera Prognostics Inc-a | +0.1% | — | Unchanged |
| 36 | PLRX | Pliant Therapeutics Inc | +0.1% | — | Unchanged |
| 37 | XNCR | Xencor Inc | +0.1% | — | Unchanged |
| 38 | ✓ | Newamsterdam Pharma Company | 0% | — | Unchanged |
| 39 | ALLKGUSD | Allakos Inc | 0% | NEW | New buy |
| 40 | INSM | Insmed Inc | 0% | — | Unchanged |
| 41 | SRRK | Scholar Rock Holding CORP | 0% | NEW | New buy |
| 42 | SRZN | Surrozen Inc | 0% | — | Unchanged |
| 43 | SCLXUSD | Scilex Holding Co | 0% | +296.75% | Add |
| 44 | ✓ | 0% | — | Unchanged | |
| 45 | ACRV | Acrivon Therapeutics Inc | — | — | Unchanged |
| 46 | TSHA | Taysha Gene Therapies Inc | — | — | Unchanged |
| 47 | RGLS | Regulus Therapeutics Inc | — | -56.07% | Trim |
| 48 | ARVN | Arvinas Inc | 0% | — | Unchanged |
| 49 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
| 50 | LXEO | Lexeo Therapeutics Inc | 0% | — | Unchanged |
According to official SEC Form 13F filings, Ra Capital Management, L.p. reported a total U.S. public equity portfolio value of $11.5B across 89 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ASND, PCVX, JANX) accounted for 28.2% of total reported equity market value during Q4 2024.
Top New Position Initiated
SEPN
市值: $160.2M
Top Position Liquidated / Trimmed
BIIB
前期市值: $229.6M
During Q4 2024, Ra Capital Management, L.p.'s top holdings by market value included ASND (18.5%)、PCVX (9.5%)、JANX (7.4%). The largest single position, ASND, represented 18.5% of total portfolio value.
In Q4 2024, Ra Capital Management, L.p. made 51 total portfolio adjustments, initiating 17 new buys, adding to 9 positions, trimming 16 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.